Physician profile
Tony Singh
NPI 1467075515
$3,134.53
in general payments reported to CMS, 2019-2025
19 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $249 · 2023: $265 · 2024: $665 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $389.72 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $361.33 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $359.98 | 2024-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $329.50 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.16 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $231.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $227.20 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $221.59 | 2021-2025 | |
| Tms Neurohealth Centers INC. | $142.17 | 2025 | Tms Neurohealth Centers INC. |
| Vanda Pharmaceuticals INC. | $124.26 | 2022-2025 | Fanapt |
| Noven Therapeutics, LLC | $85.69 | 2025 | Xelstrym |
| Orexo US, INC. | $83.80 | 2024-2025 | Zubsolv |
| Janssen Pharmaceuticals, INC | $71.31 | 2021-2022 | |
| Corium, LLC | $60.63 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $59.13 | 2025 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.95 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $38.30 | 2024 | Trintellix |
| Indivior INC. | $23.18 | 2022 | |
| Tris Pharma INC | $17.39 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.